Factors influencing decision making and antibiotic prescribing patterns for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) among non-infectious physicians in Thailand: a qualitative study.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Suluck Soontaros, Nattawut Leelakanok, Yuttaphum Mepradis, Titinun Auamnoy
{"title":"Factors influencing decision making and antibiotic prescribing patterns for the treatment of carbapenem-resistant <i>Enterobacteriaceae</i> (CRE) among non-infectious physicians in Thailand: a qualitative study.","authors":"Suluck Soontaros,&nbsp;Nattawut Leelakanok,&nbsp;Yuttaphum Mepradis,&nbsp;Titinun Auamnoy","doi":"10.12793/tcp.2022.30.e18","DOIUrl":null,"url":null,"abstract":"<p><p>The treatment of carbapenem-resistant <i>Enterobacteriaceae</i> (CRE) is diverse in each region due to the difference in local resistant patterns of CRE. We aimed to explore how physicians in Thailand decide on selection options for treating CRE infections. In this study, 25 physicians who were not infectious disease (ID) specialists participated in this semi-structured in-depth interview. We found that they, in general, did not provide empiric antibiotics for the treatment of CRE. However, some patients, e.g., those with prior carbapenems exposure may have brought CRE to physicians' attention. ID specialists played critical roles in both empiric and specific CRE treatment. There were multiple scenarios when CRE management deviated from recommendations, especially when physicians perceived that the evidence that supported the recommendations was weak. Several supportive factors, challenges, and improvements were also suggested. In conclusion, ID specialists, adequate information, and consistent implementation of infectious control policy are crucial to the treatment and prevention of CRE infection.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/42/tcp-30-187.PMC9810490.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational and Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12793/tcp.2022.30.e18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The treatment of carbapenem-resistant Enterobacteriaceae (CRE) is diverse in each region due to the difference in local resistant patterns of CRE. We aimed to explore how physicians in Thailand decide on selection options for treating CRE infections. In this study, 25 physicians who were not infectious disease (ID) specialists participated in this semi-structured in-depth interview. We found that they, in general, did not provide empiric antibiotics for the treatment of CRE. However, some patients, e.g., those with prior carbapenems exposure may have brought CRE to physicians' attention. ID specialists played critical roles in both empiric and specific CRE treatment. There were multiple scenarios when CRE management deviated from recommendations, especially when physicians perceived that the evidence that supported the recommendations was weak. Several supportive factors, challenges, and improvements were also suggested. In conclusion, ID specialists, adequate information, and consistent implementation of infectious control policy are crucial to the treatment and prevention of CRE infection.

Abstract Image

Abstract Image

Abstract Image

影响泰国非感染性医生治疗碳青霉烯类耐药肠杆菌科(CRE)的决策和抗生素处方模式的因素:一项定性研究。
由于碳青霉烯耐药肠杆菌科(CRE)的局部耐药模式存在差异,因此每个地区对CRE的治疗存在差异。我们的目的是探讨泰国的医生如何决定治疗CRE感染的选择方案。在本研究中,25名非传染病(ID)专家参加了半结构化的深度访谈。我们发现,一般来说,他们没有提供经验性抗生素治疗CRE。然而,一些患者,例如先前接触过碳青霉烯类药物的患者,可能已经引起了医生的注意。ID专家在经验性和特异性CRE治疗中都发挥了关键作用。在多种情况下,CRE管理偏离了建议,特别是当医生认为支持建议的证据不足时。还提出了一些支持因素、挑战和改进。总之,传染病专家、充分的信息和一致的感染控制政策的实施对治疗和预防CRE感染至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Translational and Clinical Pharmacology
Translational and Clinical Pharmacology Medicine-Pharmacology (medical)
CiteScore
1.60
自引率
11.10%
发文量
17
期刊介绍: Translational and Clinical Pharmacology (Transl Clin Pharmacol, TCP) is the official journal of the Korean Society for Clinical Pharmacology and Therapeutics (KSCPT). TCP is an interdisciplinary journal devoted to the dissemination of knowledge relating to all aspects of translational and clinical pharmacology. The categories for publication include pharmacokinetics (PK) and drug disposition, drug metabolism, pharmacodynamics (PD), clinical trials and design issues, pharmacogenomics and pharmacogenetics, pharmacometrics, pharmacoepidemiology, pharmacovigilence, and human pharmacology. Studies involving animal models, pharmacological characterization, and clinical trials are appropriate for consideration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信